ACE and Hyperkalemia: In the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) study, the combination of the direct renin inhibitor, aliskiren, and either an ACE inhibitor or an angiotensin receptor blocker was associated with an increased risk of renal impairment, hyperkalemia, and hypotension.